Shmuel Yaccoby
Concepts (361)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 72 | 2023 | 2998 | 5.400 |
Why?
| Osteoclasts | 18 | 2015 | 427 | 2.710 |
Why?
| Bone Diseases | 7 | 2014 | 96 | 2.270 |
Why?
| Gene Expression Regulation, Neoplastic | 14 | 2018 | 833 | 1.730 |
Why?
| Osteoblasts | 13 | 2012 | 462 | 1.460 |
Why?
| Neoplasm Proteins | 7 | 2018 | 320 | 1.300 |
Why?
| Mice, SCID | 23 | 2015 | 178 | 1.270 |
Why?
| Osteolysis | 6 | 2013 | 74 | 1.240 |
Why?
| Boronic Acids | 13 | 2013 | 183 | 1.220 |
Why?
| Coculture Techniques | 12 | 2015 | 142 | 1.180 |
Why?
| Bone Marrow | 10 | 2018 | 363 | 1.080 |
Why?
| Bone Marrow Cells | 6 | 2015 | 196 | 1.010 |
Why?
| Bone Neoplasms | 3 | 2014 | 179 | 0.990 |
Why?
| Cell Differentiation | 14 | 2018 | 640 | 0.960 |
Why?
| Bone and Bones | 9 | 2014 | 478 | 0.940 |
Why?
| Pyrazines | 12 | 2013 | 188 | 0.920 |
Why?
| Mice | 32 | 2015 | 5687 | 0.910 |
Why?
| Proteoglycans | 6 | 2008 | 83 | 0.880 |
Why?
| Protein-Tyrosine Kinases | 2 | 2014 | 88 | 0.850 |
Why?
| Cell Proliferation | 11 | 2023 | 985 | 0.800 |
Why?
| Neoplastic Stem Cells | 2 | 2017 | 98 | 0.750 |
Why?
| Cell Communication | 3 | 2015 | 68 | 0.750 |
Why?
| Animals | 35 | 2016 | 13124 | 0.710 |
Why?
| Intercellular Signaling Peptides and Proteins | 4 | 2010 | 102 | 0.700 |
Why?
| Osteogenesis | 5 | 2012 | 356 | 0.690 |
Why?
| Membrane Glycoproteins | 8 | 2009 | 245 | 0.670 |
Why?
| Bone Resorption | 4 | 2011 | 302 | 0.670 |
Why?
| Cell Movement | 6 | 2014 | 247 | 0.660 |
Why?
| Adipocytes | 2 | 2018 | 126 | 0.640 |
Why?
| Humans | 72 | 2023 | 50516 | 0.630 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.620 |
Why?
| Antineoplastic Agents | 10 | 2015 | 1172 | 0.610 |
Why?
| Gene Expression | 3 | 2018 | 610 | 0.580 |
Why?
| Gene Expression Profiling | 9 | 2023 | 1025 | 0.550 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2017 | 179 | 0.550 |
Why?
| Thalidomide | 8 | 2016 | 378 | 0.520 |
Why?
| Cell Survival | 9 | 2015 | 589 | 0.520 |
Why?
| Protease Inhibitors | 4 | 2010 | 58 | 0.520 |
Why?
| Tumor Microenvironment | 2 | 2015 | 222 | 0.510 |
Why?
| Plasma Cells | 8 | 2012 | 221 | 0.510 |
Why?
| Disease Models, Animal | 8 | 2016 | 1436 | 0.490 |
Why?
| Cytokines | 3 | 2015 | 606 | 0.490 |
Why?
| Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.470 |
Why?
| Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 6 | 0.420 |
Why?
| Angiogenesis Inhibitors | 3 | 2010 | 183 | 0.410 |
Why?
| Cell Line, Tumor | 10 | 2015 | 1398 | 0.410 |
Why?
| Mesenchymal Stem Cell Transplantation | 1 | 2012 | 19 | 0.400 |
Why?
| Rabbits | 6 | 2013 | 372 | 0.400 |
Why?
| Parathyroid Hormone | 4 | 2010 | 149 | 0.380 |
Why?
| Up-Regulation | 3 | 2013 | 446 | 0.380 |
Why?
| Wnt Proteins | 2 | 2010 | 98 | 0.370 |
Why?
| Signal Transduction | 6 | 2013 | 1624 | 0.340 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2016 | 1000 | 0.330 |
Why?
| Transplantation, Heterologous | 7 | 2009 | 75 | 0.330 |
Why?
| Receptor, EphB4 | 1 | 2009 | 5 | 0.330 |
Why?
| Ephrin-B2 | 1 | 2009 | 5 | 0.330 |
Why?
| Placenta | 1 | 2011 | 134 | 0.330 |
Why?
| Fenretinide | 1 | 2009 | 5 | 0.330 |
Why?
| Models, Biological | 4 | 2010 | 716 | 0.320 |
Why?
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2009 | 6 | 0.320 |
Why?
| Dipeptides | 1 | 2009 | 22 | 0.320 |
Why?
| Disease Progression | 8 | 2014 | 829 | 0.320 |
Why?
| Cell Adhesion Molecules | 1 | 2009 | 86 | 0.310 |
Why?
| Bone Development | 1 | 2009 | 65 | 0.300 |
Why?
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2007 | 3 | 0.290 |
Why?
| Transmembrane Activator and CAML Interactor Protein | 1 | 2007 | 6 | 0.290 |
Why?
| Extracellular Matrix Proteins | 1 | 2008 | 68 | 0.290 |
Why?
| Apoptosis | 8 | 2012 | 1097 | 0.290 |
Why?
| Bone Remodeling | 4 | 2012 | 149 | 0.280 |
Why?
| Prognosis | 12 | 2018 | 1977 | 0.280 |
Why?
| Recombinant Fusion Proteins | 1 | 2007 | 179 | 0.270 |
Why?
| Melphalan | 3 | 2016 | 178 | 0.270 |
Why?
| Tumor Cells, Cultured | 8 | 2013 | 457 | 0.260 |
Why?
| Immunohistochemistry | 5 | 2015 | 957 | 0.260 |
Why?
| Neoplasm Recurrence, Local | 3 | 2023 | 629 | 0.260 |
Why?
| Antibodies | 1 | 2006 | 153 | 0.260 |
Why?
| Cell Division | 6 | 2004 | 291 | 0.250 |
Why?
| Serine Endopeptidases | 1 | 2006 | 51 | 0.250 |
Why?
| RNA, Small Interfering | 4 | 2013 | 208 | 0.250 |
Why?
| Antigens, Neoplasm | 1 | 2006 | 148 | 0.240 |
Why?
| Severe Combined Immunodeficiency | 1 | 2005 | 12 | 0.240 |
Why?
| Neovascularization, Pathologic | 4 | 2009 | 155 | 0.240 |
Why?
| Alkaline Phosphatase | 6 | 2017 | 93 | 0.230 |
Why?
| Syndecan-1 | 6 | 2007 | 75 | 0.230 |
Why?
| NF-kappa B | 4 | 2013 | 315 | 0.230 |
Why?
| Hematopoietic Stem Cells | 3 | 2012 | 197 | 0.220 |
Why?
| Receptors, CXCR4 | 2 | 2014 | 30 | 0.220 |
Why?
| Flow Cytometry | 6 | 2015 | 474 | 0.220 |
Why?
| Gene Knockdown Techniques | 2 | 2014 | 105 | 0.220 |
Why?
| Bone Density | 3 | 2010 | 387 | 0.210 |
Why?
| Positron-Emission Tomography | 2 | 2017 | 293 | 0.210 |
Why?
| Translocation, Genetic | 2 | 2021 | 240 | 0.210 |
Why?
| Killer Cells, Natural | 2 | 2015 | 106 | 0.210 |
Why?
| Stromal Cells | 1 | 2003 | 75 | 0.200 |
Why?
| Transcription Factors | 2 | 2023 | 565 | 0.200 |
Why?
| Female | 21 | 2018 | 27086 | 0.200 |
Why?
| Neoplasm Transplantation | 3 | 2014 | 86 | 0.200 |
Why?
| Immunophenotyping | 2 | 2015 | 105 | 0.190 |
Why?
| Immunotherapy, Adoptive | 2 | 2015 | 163 | 0.190 |
Why?
| Cell Line | 2 | 2015 | 988 | 0.190 |
Why?
| T-Lymphocytes | 2 | 2015 | 325 | 0.190 |
Why?
| Immunoglobulin Light Chains | 2 | 2015 | 84 | 0.190 |
Why?
| Epigenomics | 1 | 2021 | 68 | 0.190 |
Why?
| Antibodies, Monoclonal | 4 | 2016 | 462 | 0.180 |
Why?
| Bone Transplantation | 4 | 2010 | 45 | 0.180 |
Why?
| Decorin | 2 | 2012 | 7 | 0.180 |
Why?
| Oligonucleotide Array Sequence Analysis | 4 | 2015 | 405 | 0.170 |
Why?
| Cells, Cultured | 4 | 2013 | 1571 | 0.170 |
Why?
| Drug Resistance, Neoplasm | 2 | 2015 | 316 | 0.160 |
Why?
| Neoplasm Metastasis | 2 | 2014 | 232 | 0.160 |
Why?
| Syndecans | 5 | 2006 | 37 | 0.160 |
Why?
| Genes, myc | 1 | 2019 | 32 | 0.160 |
Why?
| Cell Adhesion | 2 | 2014 | 157 | 0.160 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 572 | 0.150 |
Why?
| Male | 17 | 2018 | 25913 | 0.150 |
Why?
| Mice, Transgenic | 4 | 2007 | 540 | 0.150 |
Why?
| Risk Factors | 5 | 2018 | 3723 | 0.150 |
Why?
| Cyclin-Dependent Kinases | 2 | 2015 | 26 | 0.150 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2018 | 112 | 0.140 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 125 | 0.140 |
Why?
| Hexokinase | 1 | 2017 | 17 | 0.140 |
Why?
| Chromosome Aberrations | 3 | 2016 | 280 | 0.140 |
Why?
| Chromosomes, Human, Pair 17 | 1 | 2017 | 34 | 0.140 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2017 | 213 | 0.140 |
Why?
| Disease-Free Survival | 5 | 2018 | 444 | 0.140 |
Why?
| Calcification, Physiologic | 1 | 2017 | 40 | 0.140 |
Why?
| Proteasome Inhibitors | 2 | 2016 | 104 | 0.140 |
Why?
| Pelvis | 1 | 2017 | 66 | 0.140 |
Why?
| Stem Cells | 2 | 2009 | 166 | 0.130 |
Why?
| Chromosome Deletion | 1 | 2017 | 134 | 0.130 |
Why?
| Biopsy | 2 | 2018 | 588 | 0.130 |
Why?
| Neoplasm, Residual | 1 | 2017 | 160 | 0.130 |
Why?
| Neoplasms, Experimental | 2 | 2007 | 110 | 0.130 |
Why?
| Recurrence | 3 | 2014 | 659 | 0.130 |
Why?
| Pyridinium Compounds | 1 | 2015 | 21 | 0.130 |
Why?
| Base Sequence | 2 | 2008 | 639 | 0.130 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2017 | 189 | 0.130 |
Why?
| Endothelial Cells | 2 | 2009 | 258 | 0.130 |
Why?
| Homologous Recombination | 1 | 2015 | 41 | 0.120 |
Why?
| Benzimidazoles | 1 | 2015 | 48 | 0.120 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2015 | 212 | 0.120 |
Why?
| Peptide Nucleic Acids | 1 | 2015 | 18 | 0.120 |
Why?
| Rad51 Recombinase | 1 | 2015 | 23 | 0.120 |
Why?
| Genes, Neoplasm | 1 | 2015 | 27 | 0.120 |
Why?
| Aged | 11 | 2017 | 9743 | 0.120 |
Why?
| Bromodeoxyuridine | 2 | 2005 | 18 | 0.120 |
Why?
| Immunologic Factors | 1 | 2016 | 111 | 0.120 |
Why?
| Time Factors | 7 | 2017 | 2935 | 0.120 |
Why?
| Genomic Instability | 1 | 2015 | 90 | 0.120 |
Why?
| Diphosphonates | 2 | 2008 | 90 | 0.120 |
Why?
| Carrier Proteins | 4 | 2008 | 298 | 0.120 |
Why?
| Antigens, CD | 1 | 2015 | 222 | 0.110 |
Why?
| Asymptomatic Diseases | 1 | 2014 | 37 | 0.110 |
Why?
| Immunotherapy | 1 | 2016 | 235 | 0.110 |
Why?
| Proteome | 1 | 2015 | 169 | 0.110 |
Why?
| Interleukin-6 | 2 | 2005 | 261 | 0.110 |
Why?
| Nicotinamide Mononucleotide | 1 | 2013 | 4 | 0.110 |
Why?
| Acrylamides | 1 | 2013 | 7 | 0.110 |
Why?
| Antigens, CD19 | 2 | 2005 | 29 | 0.100 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2013 | 29 | 0.100 |
Why?
| Niacinamide | 1 | 2013 | 23 | 0.100 |
Why?
| Amides | 1 | 2013 | 35 | 0.100 |
Why?
| NAD | 1 | 2013 | 41 | 0.100 |
Why?
| Enzyme Induction | 1 | 2013 | 79 | 0.100 |
Why?
| Nitriles | 1 | 2013 | 52 | 0.100 |
Why?
| Sirtuin 1 | 1 | 2013 | 28 | 0.100 |
Why?
| Enzyme Inhibitors | 2 | 2013 | 377 | 0.100 |
Why?
| Chemokine CXCL12 | 1 | 2013 | 33 | 0.100 |
Why?
| beta Catenin | 1 | 2013 | 97 | 0.100 |
Why?
| Proteomics | 1 | 2015 | 314 | 0.100 |
Why?
| Tumor Burden | 2 | 2010 | 130 | 0.100 |
Why?
| Middle Aged | 11 | 2018 | 12613 | 0.100 |
Why?
| Oligopeptides | 1 | 2013 | 95 | 0.100 |
Why?
| Leukemia | 1 | 2013 | 65 | 0.100 |
Why?
| Myelodysplastic Syndromes | 1 | 2013 | 78 | 0.100 |
Why?
| Magnetic Resonance Imaging | 2 | 2012 | 1556 | 0.100 |
Why?
| Injections, Intravenous | 1 | 2012 | 137 | 0.100 |
Why?
| Proto-Oncogene Proteins c-jun | 2 | 2009 | 77 | 0.100 |
Why?
| Piperidines | 1 | 2013 | 99 | 0.100 |
Why?
| Cytotoxicity, Immunologic | 1 | 2012 | 55 | 0.100 |
Why?
| Myeloma Proteins | 2 | 2004 | 26 | 0.100 |
Why?
| Remission Induction | 1 | 2012 | 208 | 0.100 |
Why?
| RNA, Messenger | 3 | 2015 | 1089 | 0.100 |
Why?
| Neoplasm Staging | 3 | 2015 | 746 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 163 | 0.090 |
Why?
| Renal Insufficiency | 1 | 2012 | 110 | 0.090 |
Why?
| Glycoproteins | 2 | 2001 | 116 | 0.090 |
Why?
| Lymph Nodes | 1 | 2012 | 257 | 0.090 |
Why?
| beta 2-Microglobulin | 2 | 2007 | 39 | 0.090 |
Why?
| JNK Mitogen-Activated Protein Kinases | 2 | 2007 | 71 | 0.080 |
Why?
| Early Growth Response Protein 1 | 1 | 2009 | 34 | 0.080 |
Why?
| Myocardium | 1 | 2012 | 445 | 0.080 |
Why?
| Dexamethasone | 3 | 2007 | 432 | 0.080 |
Why?
| Sphingosine | 1 | 2009 | 28 | 0.080 |
Why?
| Organoids | 1 | 2009 | 36 | 0.080 |
Why?
| Lysophospholipids | 1 | 2009 | 44 | 0.080 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2009 | 131 | 0.080 |
Why?
| Prospective Studies | 5 | 2016 | 2378 | 0.080 |
Why?
| Caspases | 1 | 2009 | 103 | 0.080 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 93 | 0.080 |
Why?
| Leukocytes, Mononuclear | 1 | 2009 | 118 | 0.080 |
Why?
| Enzyme Activation | 1 | 2009 | 268 | 0.080 |
Why?
| Glucuronidase | 2 | 2007 | 48 | 0.080 |
Why?
| Lentivirus | 1 | 2008 | 17 | 0.080 |
Why?
| Wnt3 Protein | 1 | 2008 | 7 | 0.080 |
Why?
| Ellipticines | 1 | 2008 | 2 | 0.080 |
Why?
| Wnt3A Protein | 1 | 2008 | 10 | 0.080 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2008 | 67 | 0.070 |
Why?
| Bone Density Conservation Agents | 1 | 2009 | 74 | 0.070 |
Why?
| B-Cell Activating Factor | 1 | 2007 | 3 | 0.070 |
Why?
| Precancerous Conditions | 1 | 2008 | 82 | 0.070 |
Why?
| Cytological Techniques | 1 | 2007 | 14 | 0.070 |
Why?
| Diploidy | 1 | 2007 | 26 | 0.070 |
Why?
| Genetic Vectors | 1 | 2008 | 128 | 0.070 |
Why?
| RNA Interference | 1 | 2008 | 178 | 0.070 |
Why?
| Phosphorylation | 1 | 2009 | 525 | 0.070 |
Why?
| Karyotyping | 1 | 2007 | 65 | 0.070 |
Why?
| Heparan Sulfate Proteoglycans | 1 | 2007 | 11 | 0.070 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 577 | 0.070 |
Why?
| Kidney | 1 | 2012 | 696 | 0.070 |
Why?
| Reactive Oxygen Species | 1 | 2009 | 409 | 0.070 |
Why?
| Receptor Activator of Nuclear Factor-kappa B | 2 | 2004 | 33 | 0.070 |
Why?
| Mice, Inbred C57BL | 1 | 2012 | 1808 | 0.070 |
Why?
| Phenotype | 2 | 2009 | 739 | 0.070 |
Why?
| Models, Animal | 1 | 2007 | 227 | 0.070 |
Why?
| Immunosuppressive Agents | 1 | 2008 | 225 | 0.070 |
Why?
| Treatment Outcome | 6 | 2017 | 5285 | 0.070 |
Why?
| Risk Assessment | 3 | 2018 | 1269 | 0.060 |
Why?
| Gelatinases | 1 | 2006 | 32 | 0.060 |
Why?
| Endopeptidases | 1 | 2006 | 65 | 0.060 |
Why?
| Survival Analysis | 2 | 2018 | 661 | 0.060 |
Why?
| Adult | 6 | 2018 | 13584 | 0.060 |
Why?
| Antigens, CD34 | 1 | 2005 | 75 | 0.060 |
Why?
| RANK Ligand | 2 | 2004 | 187 | 0.060 |
Why?
| Fetal Tissue Transplantation | 1 | 2005 | 10 | 0.060 |
Why?
| Hematologic Neoplasms | 1 | 2006 | 99 | 0.060 |
Why?
| Metaphase | 2 | 2016 | 45 | 0.060 |
Why?
| Molecular Sequence Data | 1 | 2006 | 778 | 0.060 |
Why?
| Endothelium, Vascular | 1 | 2006 | 251 | 0.060 |
Why?
| Annexin A5 | 1 | 2004 | 14 | 0.060 |
Why?
| Culture Media, Conditioned | 1 | 2004 | 47 | 0.060 |
Why?
| Phagocytosis | 1 | 2004 | 44 | 0.060 |
Why?
| Survival Rate | 2 | 2018 | 909 | 0.060 |
Why?
| Clinical Trials as Topic | 3 | 2016 | 486 | 0.060 |
Why?
| Membrane Proteins | 1 | 2006 | 332 | 0.050 |
Why?
| Pregnancy | 1 | 2011 | 2451 | 0.050 |
Why?
| Polymerase Chain Reaction | 1 | 2005 | 449 | 0.050 |
Why?
| Endothelial Growth Factors | 1 | 2002 | 9 | 0.050 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2002 | 13 | 0.050 |
Why?
| Lymphokines | 1 | 2002 | 19 | 0.050 |
Why?
| Biotransformation | 1 | 2002 | 84 | 0.050 |
Why?
| Oxidative Stress | 1 | 2007 | 772 | 0.050 |
Why?
| Blotting, Western | 2 | 2015 | 578 | 0.050 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2002 | 182 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 57 | 0.050 |
Why?
| Combined Modality Therapy | 2 | 2016 | 641 | 0.050 |
Why?
| Imidazoles | 1 | 2002 | 127 | 0.050 |
Why?
| Chromatin | 1 | 2021 | 137 | 0.050 |
Why?
| Polycomb Repressive Complex 2 | 1 | 2021 | 46 | 0.050 |
Why?
| Cell Polarity | 1 | 2000 | 17 | 0.040 |
Why?
| Liver Transplantation | 1 | 2002 | 154 | 0.040 |
Why?
| Cell Transplantation | 1 | 1999 | 3 | 0.040 |
Why?
| Mice, Inbred ICR | 1 | 1999 | 23 | 0.040 |
Why?
| Histones | 1 | 2021 | 297 | 0.040 |
Why?
| Cell Membrane | 1 | 2000 | 246 | 0.040 |
Why?
| Protein Disulfide-Isomerases | 1 | 2019 | 14 | 0.040 |
Why?
| Genes, Immunoglobulin Heavy Chain | 1 | 2019 | 12 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 1372 | 0.040 |
Why?
| Radiation Chimera | 1 | 1998 | 4 | 0.040 |
Why?
| Osteoprotegerin | 3 | 2006 | 54 | 0.040 |
Why?
| Aged, 80 and over | 2 | 2017 | 3227 | 0.040 |
Why?
| Clone Cells | 1 | 1998 | 70 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2012 | 583 | 0.040 |
Why?
| Radiography | 2 | 2012 | 486 | 0.040 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2019 | 231 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 418 | 0.040 |
Why?
| Tomography, X-Ray Computed | 2 | 2017 | 1169 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 59 | 0.030 |
Why?
| Liver | 1 | 2002 | 1132 | 0.030 |
Why?
| Indolizines | 1 | 2015 | 5 | 0.030 |
Why?
| Cyclic N-Oxides | 1 | 2015 | 13 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 151 | 0.030 |
Why?
| Transcriptome | 1 | 2018 | 314 | 0.030 |
Why?
| Drug Synergism | 1 | 2015 | 151 | 0.030 |
Why?
| S Phase | 1 | 2015 | 18 | 0.030 |
Why?
| Genes, BRCA1 | 1 | 2015 | 19 | 0.030 |
Why?
| Follow-Up Studies | 2 | 2013 | 2242 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 181 | 0.030 |
Why?
| Predictive Value of Tests | 2 | 2007 | 930 | 0.030 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 234 | 0.030 |
Why?
| Transcription, Genetic | 1 | 2015 | 361 | 0.030 |
Why?
| DNA Damage | 1 | 2015 | 301 | 0.030 |
Why?
| Transfection | 2 | 2004 | 356 | 0.030 |
Why?
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 8 | 0.020 |
Why?
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 9 | 0.020 |
Why?
| Acute Disease | 1 | 2013 | 373 | 0.020 |
Why?
| Interleukin-2 | 1 | 2012 | 71 | 0.020 |
Why?
| Mice, Inbred NOD | 1 | 2012 | 91 | 0.020 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 137 | 0.020 |
Why?
| Creatinine | 1 | 2012 | 145 | 0.020 |
Why?
| Glomerular Filtration Rate | 1 | 2012 | 119 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2012 | 164 | 0.020 |
Why?
| Receptors, Tumor Necrosis Factor | 2 | 2001 | 38 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2012 | 144 | 0.020 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2001 | 68 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2012 | 415 | 0.020 |
Why?
| Radiation-Sensitizing Agents | 1 | 2010 | 51 | 0.020 |
Why?
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 21 | 0.020 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 12 | 0.020 |
Why?
| Incidence | 1 | 2013 | 1032 | 0.020 |
Why?
| Protein Transport | 1 | 2010 | 181 | 0.020 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 66 | 0.020 |
Why?
| Peptides | 1 | 2010 | 221 | 0.020 |
Why?
| Down-Regulation | 1 | 2009 | 340 | 0.020 |
Why?
| CDC2-CDC28 Kinases | 1 | 2008 | 11 | 0.020 |
Why?
| Salvage Therapy | 1 | 2008 | 137 | 0.020 |
Why?
| Protein Binding | 1 | 2009 | 654 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 226 | 0.020 |
Why?
| Proteins | 1 | 2010 | 339 | 0.020 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2007 | 49 | 0.020 |
Why?
| Retrospective Studies | 2 | 2012 | 6264 | 0.020 |
Why?
| Cytogenetic Analysis | 1 | 2007 | 74 | 0.020 |
Why?
| Phospholipase C gamma | 1 | 2006 | 4 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2007 | 277 | 0.020 |
Why?
| Caspase 9 | 1 | 2006 | 14 | 0.020 |
Why?
| Cell Cycle | 1 | 2008 | 226 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 49 | 0.020 |
Why?
| Cyclin D | 1 | 2006 | 18 | 0.020 |
Why?
| Cyclins | 1 | 2006 | 38 | 0.020 |
Why?
| Bone Marrow Transplantation | 1 | 2007 | 136 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2006 | 43 | 0.020 |
Why?
| src-Family Kinases | 1 | 2006 | 51 | 0.020 |
Why?
| Case-Control Studies | 1 | 2009 | 1155 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 156 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2006 | 296 | 0.020 |
Why?
| Chromosome Mapping | 1 | 2006 | 153 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 140 | 0.020 |
Why?
| Cluster Analysis | 1 | 2006 | 219 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2007 | 464 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 162 | 0.020 |
Why?
| Transplantation, Autologous | 1 | 2007 | 481 | 0.010 |
Why?
| Logistic Models | 1 | 2007 | 899 | 0.010 |
Why?
| DNA, Complementary | 1 | 2004 | 133 | 0.010 |
Why?
| Young Adult | 1 | 2013 | 4107 | 0.010 |
Why?
| Recombinant Proteins | 1 | 2004 | 476 | 0.010 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2005 | 573 | 0.010 |
Why?
| Solubility | 1 | 2002 | 71 | 0.010 |
Why?
| Leukemia, Plasma Cell | 1 | 2002 | 32 | 0.010 |
Why?
| Acid Phosphatase | 1 | 2001 | 12 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2002 | 245 | 0.010 |
Why?
| Adolescent | 1 | 2013 | 6446 | 0.010 |
Why?
| Neoplasm Invasiveness | 1 | 2002 | 269 | 0.010 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2001 | 46 | 0.010 |
Why?
| Hodgkin Disease | 1 | 2001 | 47 | 0.010 |
Why?
| Isoenzymes | 1 | 2001 | 168 | 0.010 |
Why?
| Reference Values | 1 | 2001 | 307 | 0.010 |
Why?
| Paraproteinemias | 1 | 2001 | 72 | 0.010 |
Why?
| LDL-Receptor Related Protein-Associated Protein | 1 | 2000 | 1 | 0.010 |
Why?
| Hepatocyte Growth Factor | 1 | 2000 | 10 | 0.010 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 62 | 0.010 |
Why?
| Epithelial Cells | 1 | 2000 | 207 | 0.010 |
Why?
|
|
Yaccoby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|